Summary The intrinsic radiosensitivity of cervical carcinoma has been measured using a soft agar clonogenic assay. All patients received radical radiotherapy alone with a minimum of 2 years post-treatment follow-up. Only women with stage I, II and III disease were included in the analysis. Values for cell surviving fraction at 2 Gy (SF2) were obtained for 88 tumours with an assay success rate of 73%. The 53 patients alive and well at the time of analysis had tumours with a mean SF2 that was significantly lower than the value from the 22 patients with locoregional failure (P < 0.01). Patients with radioresistant tumours (SF2> 0.40, the median) had a significantly lower 3 year survival level than those with sensitive tumours (SF2 < 0.40) (P = 0.002). Also the frequency of local recurrence was higher (P = 0.001) whether these were central (P = 0.009) or peripheral (P = 0.046). Cell surviving fraction at 3.5 Gy was obtained for 46 tumours and the 3 year patient survival rate was significantly higher for those with SF3.5 values less than the median (P = 0.043). There was, however, no difference in the level of local recurrence (P = 0.24). The ability to grow in culture was not associated with significantly poorer patient survival (P = 0.56) or failure to control the primary disease (P = 0.17). While high colony forming efficiencies were associated with an increased rate of local recurrence (P = 0.029) they did not predict for overall patient survival (P = 0.32). These data suggest that, for cervical carcinoma treated with radical radiotherapy, intrinsic radiosensitivity is important in determining treatment outcome.
A number of laboratory-based potential prognostic factors for the radiotherapy of cancer are under investigation. Of particular interest are tumour oxygenation (Hockel et al., 1993) , proliferation (Begg et al., 1990) and radiosensitivity . One or some of these may eventually enable the prediction of treatment response and would thus provide a useful tool in the planning of patient care. Such individualisation of therapy should ultimately lead to improvements in the survival figures for patients with various cancers and reduce treatment morbidity.
Recent interest in assays of radiosensitivity stems from the reports of a correlation between the ability to control various classes of tumour and parameters that describe the initial portion of cell survival curves derived from the tumours (Malaise et al., 1987) . These parameters are surviving fraction at 2 Gy (SF2), the initial slope (a) and the mean inactivation dose (D, the integral of fitted curves). Experimental studies have subsequently supported these observations and shown that, in animal models, SF2, measured in vitro, can predict response to in vivo irradiation (reviewed in West & Hendry, 1992) .
A number of projects have now been set up to evaluate the usefulness of pre-treatment assessments of intrinsic radiosensitivity. Our own correlations of SF2 with early outcome following radiotherapy in cervical cancer have been encouraging (West et al., 1989; 1991a; . In addition, preliminary results are emerging from work being carried out using the cell adhesive matrix (CAM) assay on squamous cell carcinomas (head and neck, cervix) treated predominantly by radiotherapy alone. These also suggest that measurements of intrinsic radiosensitivity can predict response to treatment (Grinsky et al., 1992) . In contrast a study using the CAM assay on advanced head and neck cancers treated by postoperative radiotherapy has yielded less favourable results .
This report is an update on radiosensitivity testing studies carried out at the Christie Hospital in Manchester. The work is an investigation into the ability of SF2, measured using the Courtenay-Mills soft agar assay, to predict patient outcome for stage I -III carcinoma of the cervix treated with radiotherapy alone. All patients have had a minimum of 2 years follow-up.
Materials and methods

Patients
Tumour biopsies were taken under anaesthetic from patients with proven carcinoma of the cervix, immediately prior to treatment with radiotherapy. Parallel specimens were sent to histopathology for assessment of the histological type and grade. All patients included in the analysis were treated radically using the techniques and dosage schedules of the Manchester School (Hunter, 1991 
Tumour disaggregation
The tissue was minced and placed in basal medium Eagle's (Gibco, Paisley, Scotland; 50 ml per 0.5 g) supplemented with 20 glg ml-' amphotericin (Sigma, Poole, UK), 200 pg ml-' gentamicin (Sigma), 15 mM Hepes (Gibco), 0.5 mg ml-' pronase (Boehringer, Germany), 0.5 mg ml-' collagenase (Sigma) and 0.4 mg ml1 deoxyribonuclease I (Sigma). After 1.5 h at 37°C in a shaking water bath, the supernatant was collected and placed on ice while the specimen was digested for a further 0.5 h with 0.05% trypsin (Worthington Diagnostics Ltd, Freehold, New Jersey, USA; 50 ml per 0.5 g). Following disaggregation the tumour material was filtered, washed and resuspended in growth medium (Ham's F 12 (Gibco) plus 15% foetal calf serum (Biological Industries), 2 pg ml-' amphotericin, 25 pg ml-' gentamicin, 10 ng ml-' epidermal growth factor (Sigma), 10 fig ml-' insulin (Collaborative Research), 0.5 fig ml-' hydrocortisone (Sigma) and 2.5 jig ml-' transferrin (Sigma)). The resulting cell suspension was filtered through a 37 lim screen and a viable cell count obtained (trypan blue-exclusion).
Clonogenic assay Clonogenicity was determined using the Courtenay-Mills soft agar assay (Courtenay & Mills, 1978; Wilks & West, 1991) . Tumour single-cell suspensions (0.5 ml at ten times the required concentration) and 0. The ability of SF2 measurements to predict treatment outcome is illustrated in Figure 2 where the SF2 values have been stratified into two halves. Patients (20 dead/42) with radioresistant tumours had a significantly lower 3 year survival rate than those (7 dead/46) with sensitive tumour cells 
Results
Validation of the Courtenay-Mills assay used in this study has been reported previously. Preliminary work demonstrated the malignant epithelial origin of the colonies , linearity of colony number with cells plated, the ability to produce radiation survival curves, that intratumour heterogeneity was not a limitation to measurements of SF2 and that there were statistically significant differences in the radiosensitivity of individual tumours (West et al., 1989; Davidson et al., 1990) .
Over a 56 month period 156 tumours were received. There was insufficient material following disaggregation in 7. These specimens all weighed less than 0.1 g and 6 were stage lb (P = 0.002). Also the frequency of local recurrence was higher (17/42 vs 5/46; P = 0.001) whether these were central (9/42 vs 2/46; P = 0.009) or peripheral (8/42 vs 3/46; P = 0.046). The SF2 values were also divided into four quar-54 tiles (Figure 2 (Figure 3) . The 3 year survival levels were 88, 57 and 62% for stage I, II and III disease respectively and the trend for poorer survival with increasing stage was significant (P = 0.023). However, tumour stage was a poor prognostic factor for the probability of local failure (P = 0.28), indicating it to be a better predictor of the likelihood of metastatic spread (i.e. nodal disease). The 54 predictive potential of SF2 measurements for the individual stages was also examined (Figure 4) . The number of local failures for the SF2 < 0.40 and SF2 >0.40 groups respectively were 1/18 and 5/14 -stage I, 3/18 and 6/17 -stage II and 1/10 and 6/11 -stage III disease. Neither tumour grade nor patient age influenced survival or the ability of radiotherapy to control locoregional disease (P>0.73). The patients were so divided into two groups for those above and below the median age of 50. SF2 predicted local recurrence for the younger age group only ( Figure 5 ). However because of the numbers involved, the difference between the two age groups was not significant and after allowing for SF2, age was not a significant prognostic factor (P = 0.40). Surviving fraction at 3.5 Gy (SF3.5) was obtained for 46 tumours (Table II) . The 3 year survival rate was significantly higher for patients with SF3.5 values less than or equal to the median of 0.175 (19/23 vs 13/23; P = 0.043). However there was no difference in the level of local recurrence with five and eight recurrences in the sensitive and resistant bands respectively (P = 0.24).
The ability to grow, in culture was investigated for 119 patients, which included 21 patients whose tumours failed to meet the criterion for growth in culture and ten patients for whom CFE only was obtained. For this larger data set, stage at presentation was important in determining both survival (P <0.00 1) and local failure (P = 0.005). For the no growth group, five or 21 patients died, two of local recurrence. While for the growth set, 31 of 98 patients died, 24 of local recurrence. Despite the weak trend for patients with tumours that grew in culture to respond better to treatment, the difference was not significant for either survival (P = 0.56) or failure to control the primary disease (P = 0.17). However, the ability to grow in culture showed a correlation with clinical stage; 14/52 stage I tumours did not grow compared to 7/67 stage II and III tumours (P = 0.036; X2 test).
High CFEs (greater than the median of 0.06%) were associated with an increased rate of local recurrence (15/42 vs 7/46; P = 0.029) but only for those occurring in the centre (9/42 vs 2/47; P = 0.014) rather than at the periphery (5/46 vs 6/42; P = 0.53) of the radiation field. CFE did not predict for overall survival with 63% 3 year survival in the high and 71% in the low CFE groups (P = 0.32).
Discussion
Using the Courtenay-Mills assay clonogenic growth was obtained in 79% of the tumour specimens. Although the success rate for measuring SF2 was only 73%, this could be increased if larger biopsies were taken as in this study only half of each tumour specimen was available. The overall success rate for obtaining SF2 values was 88/139 (63%). This would not be a limitation to radiosensitivity testing if the ability of a tumour specimens to grow in culture was associated with an increased level of local recurrence and lower rates of survival. Although these trends were observed, the differences in survival/local control between the growth and no-growth groups were not significant. This supports the work of others which has shown that patients whose in vitro cell cultures failed did not fare significantly better than those for whom successful cell cultures were obtained (Girinsky et al., 1992) . However, there was a significant correlation between growth potential and stage with a higher proportion of stage I compared to stage II and III tumours failing to grow well in culture. High CFEs were associated with a significant increase in local recurrence rates but did not predict survival and the latter finding confirms a previous report by us on a smaller group of patients . The correlation between SF2 and failure to control local disease agrees with our earlier reports on smaller data sets (West et al., 1991a,b) . A similar result has recently been described by Girinsky and co-workers using the CAM assay on a mixed group of head and neck and cervix tumours (Girinsky et al., 1992) . In contrast, another large study using the CAM assay on head and neck cancers treated with radiotherapy plus surgery has failed to show a significant correlation between intrinsic radiosensitivity and treatment outcome . This may be because SF2 (or a) will be a better predictor for patient outcome following radiotherapy alone rather than when combined with surgery. Alternatively it may reflect the different proportions of the various disease sites included in the analyses, with for example 69% (Girinsky et al., 1992) vs 22% oropharynx tumours in the two studies. Use of the CAM assay has been criticised due to its failure to suppress fibroblast growth (Parkins & Steel, 1990) . However, the results of Girinsky and co-workers (1992) support its use in clinical studies. As the CAM is more rapid than the Courtenay-Mills assay used in this work, the results of its use in cervix cancers treated with radiotherapy alone will be of interest.
In this study, for the larger tumour specimens obtained, radiosensitivity was also assessed as SF3.5. Although this was carried out as an experimental check to ensure that SF3.5 values were lower than those at 2 Gy, it was of interest to evaluate the ability of SF3.5 to predict patient outcome. Using published radiation cell survival curves, the capacity of survival levels to discriminate between groups of tumours differing in clinical radiocurability has been shown to be dose dependent between 1 and 6 Gy. The relationship showed a bell-shaped curve with a peak between 1.5 and 2 Gy (Malaise et al., 1987) . The results reported here show that, for the small numbers of tumours examined, SF3.5 values did not predict for local recurrence although they did predict for overall survival (P = 0.043). Therefore, these clinical data support the observations made using cell lines that SF3.5 is less effective than SF2 in predicting radiocurability.
The predictive potential of measurements of SF2 was investigated separately for stage I, II and III disease. Although the Age <50
1.0 -4-0 c 0 0 -j same trend was seen for all disease stages the results were only significant for stage III disease. It may be that intrinsic radiosensitivity is more important for bulkier tumours. However larger numbers of patients need be accrued before any definite conclusions can be drawn. For the data set analysed, stage alone was poorer than SF2 at predicting patient outcome. This may be partly explained by the size of the tumours obtained. All stage I tumours were classified as lb and many were bulky tumours. It should be noted that for small tumours there would be insufficient material available for cell cultures to be carried out. This is supported by the observation of a higher than expected level of local recurrence for stage I carcinoma of the cervix.
The importance of age in carcinoma of the cervix has not been clearly defined. Although there are some reports of a poorer prognosis for younger patients (e.g. Elliot et al., 1989) others have shown the opposite (e.g. Russell et al., 1987) . For the group of patients analysed as part of this study, age was not a significant prognostic factor, either alone or after allowing for SF2. However, an interesting trend of the data was the observation that SF2 may have more value in younger patients. As with the other subsets analysed more numbers must be accrued before firm conclusions can be drawn. Nevertheless, if the finding can be verified with larger patient numbers then they may suggest a possible hormonal influence with perhaps intrinsic radiosensitivity being more important for pre-menopausal women. If this proves to be the case then, as there was no difference in treatment outcome between patients older or younger than the median age, some other factor must be dominating response to radiotherapy for the older women.
There are a number of radiobiological parameters that would be expected to influence radiotherapy treatment outcome. A mathematical study concluded that predictive assays based on estimates of intrinsic tumour cell radiosensitivity are likely to be more accurate in predicting tumour response than assays based on clonogen doubling time, extent of hypoxia or clonogen number (Tucker & Thames, 1989) . For the patients analysed as part of this report, five with radiosensitive tumours recurred locally. Of these five, two had values for CFE that fell well above the median (0.23 and 0.66%). Another with a CFE just above the median was a bulky tumour (5 x 5 x 6 cm). This tumour also had a high Ki67 index (.301 compared to a median of .190; S. Glew, personal communication) suggesting a high rate of tumour proliferation. It is likely that the future of predictive testing lies in the assessment of multiple parameters which include measures of radiosensitivity, hypoxia, proliferation and maybe even clonogen number. For this to be feasible on a routine basis assays are required that are not only rapid and reliable but also either require just a small amount of tissue or are non-invasive.
In conclusion these results support the idea that intrinsic radiosensitivity influences response to radiotherapy particularly in large tumours. They also suggest that in vitro measurements of SF2 can predict patient outcome for cervical carcinoma treated with radiotherapy alone. These findings should also encourage the development of alternative assays for radiosensitivity testing that are rapid, reliable and feasible for large scale routine clinical use.
